CR: complete remission PR: partial response RE: Pt: patient CI: confidence intervals N: number ns: not significant. (J) Cytotoxic function of antigen-specific cytotoxic T lymphocytes on target cells, (a) T2 cells plus p540 peptide, (b) as (a) plus stimulated CD8 +CD28 + T cells, (c) as (a) plus stimulated CD8 +CD28 – T cells. (F-I) Suppressive activities of CD8 +CD28 + and CD8 +CD28 – T cells were analyzed, (a and d) mononuclear cell proliferation plus anti-CD3 monoclonal antibodies in the presence of autologous irradiated monocytes, (b) as (a) plus freshly isolated CD8 +CD28 + T cells, (c) as (a) plus freshly isolated CD8 +CD28 – T cells, (d and e) as (b and c) plus IL-2 and granulocyte-macrophage colony-stimulating factor stimulation. (E) Area under curve (AUC) details of each subgroup. Receiver operating characteristic curves of T cells and their balance in predicting the disease stage diagonal lines in (D) are the diagnostic reference lines. Average frequency of CD8 +CD28 + T cells, CD8 +CD28- T cells, and CD8 +CD28 +/CD8 +CD28 – ratio in patients (A-C). Taken together, tandem auto-HSCT can be considered an optimal strategy for adult T-LBL patients (ChiCTR-ONN-16008480).ĬD8 +CD28 +/CD8 +CD28 – equilibrium could predict the disease status of T-cell lymphoblastic lymphoma patients. In addition, diagnostic models of the initial CD8+CD28+/CD8+CD28- T cell ratio in predicting the disease status were found to be significant. Multivariate analysis identified that disease status after the first transplantation was the only independent prognostic factor for patients treated with tandem-HSCT. In the tandem auto-HSCT group, age and disease status after the first transplantation impacted the OS and PFS. The 3-year PFS and OS rate of the tandem auto-HSCT group (73.5% and 76.3%) were significantly higher than those of the single auto-HSCT group (46.9% and 58.3%) and the chemotherapy group (45.1% and 57.1%). The median follow-up time was 37 months, the 3-year progression/relapse rate of the tandem auto-HSCT group was significantly lower than that of the single auto-HSCT group and chemotherapy group (26.5% vs 53.1% and 54.8%). MM accounted for 155,688 newly diagnosed cases in 2019 and approximately 100,000 deaths annually worldwide. 181 Newly-diagnosed adult T-LBL patients were enrolled, 89 patients were treated with chemotherapy alone, 46 patients were allocated to single auto-HSCT group, 46 patients were treated with tandem auto-HSCT. Multiple myeloma (MM), one of the most common hematologic malignancies, is characterized by abnormal monoclonal expansion of plasma cells in the bone marrow. In this study, we assessed the safety and efficacy of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) strategy for adult T-LBL and evaluated prognostic factors affecting survival. T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive form of lymphoma with poor clinical outcomes and lacks of a standard treatment regimen.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |